Compare AU
Compare CURE vs. QMIX
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Global X S&P Biotech ETF (CURE) and the SPDR MSCI World Quality Mix Fund (QMIX). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
CURE | QMIX | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 79 | 17 |
Median incremental investment | $624.65 | $2,797.41 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,353.14 | $4,161.28 |
Average age group | > 35 | > 35 |
Key Summary
CURE | QMIX | |
|---|---|---|
Strategy | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. | QMIX.AX was created on 2015-09-11 by SPDR. The fund's investment portfolio concentrates primarily on total market equity. The ETF currently has 351.67m in AUM and 1080 holdings. The SPDR MSCI World Quality Mix Fund seeks to provide investment results that, before fees and expenses,correspond generally to the return performance of the MSCI World Factor Mix A-Series Index (previously namedthe MSCI World Quality Mix Index), assuming all payments from the index constituents are reinvested. |
Top 3 holdings | AbbVie Inc (2.62 %) Alnylam Pharmaceuticals Inc (2.59 %) Amgen Inc (2.59 %) | Apple Inc (2.50 %) Microsoft Corp (2.21 %) Meta Platforms Inc Class A (2.04 %) |
Top 3 industries | Health Care (100.00 %) Other (10.24 %) | Information Technology (40.59 %) Health Care (22.58 %) Communication Services (21.08 %) |
Top 3 countries | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) | United States (67.46 %) Japan (7.23 %) United Kingdom of Great Britain and Northern Ireland (3.87 %) |
Management fee | 0.45 % | 0.18 % |
Key Summary
CURE | QMIX | |
|---|---|---|
Issuer | Global X | SPDR |
Tracking index | S&P Biotechnology Select Industry | MSCI WORLD FACTOR MIX A-SERIES INDEX - USD |
Asset class | ETF | ETF |
Management fee | 0.45 % | 0.18 % |
Price | $46.66 | $32.51 |
Size | $33.491 million | $347.792 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 4.24 % | 3.95 % |
Market | ASX | ASX |
First listed date | 12/11/2018 | 14/09/2015 |
Purchase fee | $6.50 | $6.50 |
Community Stats
CURE | QMIX | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 79 | 17 |
Median incremental investment | $624.65 | $2,797.41 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,353.14 | $4,161.28 |
Average age group | > 35 | > 35 |
Pros and Cons
CURE | QMIX | |
|---|---|---|
Pros |
|
|
Cons |
|
|
CURE | QMIX |
|---|---|
Lower exposure to AU market | Higher exposure to AU market |
Higher exposure to US market | Lower exposure to US market |
Higher management fee | Lower management fee |
Lower price growth | Higher price growth |
Higher distribution yield | Lower distribution yield |